WELL:SW:SW-HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF (CHF)

ETF | Others |

Last Closing

USD 5.971

Change

0.00 (0.00)%

Market Cap

N/A

Volume

900.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-19 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

-0.05 (-0.42%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.15 (-0.76%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.44 (-1.65%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+56.00 (+1.08%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+35.40 (+2.20%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+5.50 (+0.25%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

-0.76 (-1.03%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

-0.52 (-0.48%)

USD 130,595.12B

ETFs Containing WELL:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.18% 6% D- 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.18% 6% D- 13% F
Trailing 12 Months  
Capital Gain 3.20% 23% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.20% 21% F 27% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.94% 9% A- 12% F
Dividend Return -1.94% 9% A- 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.00% 66% D+ 70% C-
Risk Adjusted Return -32.41% 10% F 12% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CHF)

Quarterly Financials (CHF)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.